Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes

Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel...

Full description

Saved in:
Bibliographic Details
Published inACS omega Vol. 6; no. 12; pp. 8271 - 8278
Main Authors Wang, Rijun, Wang, Ning, Han, Yuping, Xu, Jiyao, Xu, Zesheng
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 30.03.2021
Online AccessGet full text
ISSN2470-1343
2470-1343
DOI10.1021/acsomega.0c06326

Cover

Abstract Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes. Methods: LPS was used to induce an in vitro injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus. Results: First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway. Conclusions: Dulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress.
AbstractList Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes. Methods: LPS was used to induce an in vitro injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus. Results: First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway. Conclusions: Dulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress.
Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes. Methods: LPS was used to induce an in vitro injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus. Results: First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway. Conclusions: Dulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress.
Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes. LPS was used to induce an injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus. First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway. Dulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress.
Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes.BACKGROUND AND PURPOSESepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and oxidative stress are reported to be involved in the development of sepsis-induced cardiomyopathy. Dulaglutide is a novel antidiabetic agent that is currently reported to exert an anti-inflammatory effect. The present study aims to explore the potential protective property of dulaglutide on lipopolysaccharide (LPS)-induced injury on cardiomyocytes.LPS was used to induce an in vitro injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus.METHODSLPS was used to induce an in vitro injury model on cardiomyocytes. The mitochondrial reactive oxygen species (ROS) level was detected using MitoSOX red, and reduced glutathione (GSH) was measured to evaluate the status of oxidative stress in H9c2 myocardial cells. The expressions of NADPH oxidase-1 (NOX-1) and inducible nitric oxidesynthase (iNOS) were determined using real-time PCR and western blot analysis. Real-time PCR and enzyme-linked immunosorbent assay (ELISA) were both used to detect the expressions and concentrations of tumor necrosis factor-α, interleukin-1β, interleukin-17, matrix metalloproteinase-2, and matrix metalloproteinase-9 in H9c2 myocardial cells, respectively. The production of nitric oxide (NO) was measured using the Griess reagent. The levels of creatine kinase isoenzyme-MB (CK-MB) and cardiac troponin I (cTnI) were detected using ELISA. Western blot was utilized to determine the expressions of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p-NF-κB p65 in H9c2 myocardial cells in the nucleus.First, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway.RESULTSFirst, dulaglutide ameliorated LPS-induced oxidative stress by suppressing the production of mitochondrial ROS and elevating the level of reduced GSH, as well as downregulating NOX-1. Second, the LPS-induced cardiomyocyte injury was alleviated by dulaglutide through downregulating CK-MB and cTnI, accompanied by inhibiting iNOS expression and NO production. Lastly, the production of inflammatory factors and upregulation of MMPs induced by LPS were both significantly reversed by dulaglutide through suppressing the TLR4/Myd88/NF-κB signaling pathway.Dulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress.CONCLUSIONSDulaglutide alleviated LPS-induced injury in cardiomyocytes by inhibiting inflammation and oxidative stress.
Author Wang, Ning
Wang, Rijun
Han, Yuping
Xu, Zesheng
Xu, Jiyao
AuthorAffiliation Cangzhou Central Hospital Affiliated of Tianjin Medical University
Department of Cornea
Shanxi Ophthalmic Hospital
Shanxi Cardiovascular Hospital
Department of Cardiology
AuthorAffiliation_xml – name: Department of Cardiology
– name: Shanxi Ophthalmic Hospital
– name: Shanxi Cardiovascular Hospital
– name: Department of Cornea
– name: Cangzhou Central Hospital Affiliated of Tianjin Medical University
Author_xml – sequence: 1
  givenname: Rijun
  surname: Wang
  fullname: Wang, Rijun
  organization: Shanxi Cardiovascular Hospital
– sequence: 2
  givenname: Ning
  surname: Wang
  fullname: Wang, Ning
  organization: Shanxi Cardiovascular Hospital
– sequence: 3
  givenname: Yuping
  surname: Han
  fullname: Han, Yuping
  organization: Shanxi Ophthalmic Hospital
– sequence: 4
  givenname: Jiyao
  surname: Xu
  fullname: Xu, Jiyao
  organization: Shanxi Cardiovascular Hospital
– sequence: 5
  givenname: Zesheng
  orcidid: 0000-0001-6435-2724
  surname: Xu
  fullname: Xu, Zesheng
  email: xuzesheng1966@163.com
  organization: Cangzhou Central Hospital Affiliated of Tianjin Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33817486$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtr3DAUhUVJaB7NvqviZRd1qoctSxQKYdq0AwMJtF2L62tpqkG2UskOzL-vk5mEpNCs9LjnfPdK54QcDHGwhLxl9JxRzj4C5tjbNZxTpFJw-Yoc86qhJROVOHiyPyJnOW8opUwqrrh8TY6EUKyplDwmn75MAdZhGn1ni4sQ7K2H0eZidf2jXA7dhLYrlsNmStvCD8UCUudjv424nUVvyKGDkO3Zfj0lvy6__lx8L1dX35aLi1UJldZjaZmQTjqhhW7qCkBa23BdO1S2rVAgqFoAco2Ou_mgKpScuhYloGOtpuKULHfcLsLG3CTfQ9qaCN7cX8S0NpBGj8GaGjvGGt20rrFVDaCFU6jrhjeUA7RuZn3esW6mtrcd2mFMEJ5Bn1cG_9us461RlNXzQ2bA-z0gxT-TzaPpfUYbAgw2Ttnwmiqlpbqf-93TXo9NHn5_FtCdAFPMOVn3KGHU3GVsHjI2-4xni_zHgn6E0ce7aX14yfhhZ5wrZhOnNMyR_V_-F3pmvY8
CitedBy_id crossref_primary_10_1536_ihj_23_576
crossref_primary_10_1615_CritRevImmunol_2023050050
crossref_primary_10_1016_j_heliyon_2023_e13330
crossref_primary_10_1016_j_jafr_2024_101034
crossref_primary_10_3389_fphar_2022_868393
crossref_primary_10_1002_cbdv_202401224
crossref_primary_10_1007_s00011_024_01950_0
crossref_primary_10_1007_s00210_024_03631_5
crossref_primary_10_1002_ptr_7693
crossref_primary_10_1007_s00394_024_03549_x
crossref_primary_10_1002_fft2_441
crossref_primary_10_1161_JAHA_122_026728
crossref_primary_10_3390_molecules27155037
crossref_primary_10_3390_ph17040525
crossref_primary_10_3390_pharmaceutics16060693
crossref_primary_10_1186_s12933_022_01634_1
crossref_primary_10_1186_s10020_024_00912_w
crossref_primary_10_1016_j_jff_2022_105304
crossref_primary_10_1038_s41420_022_01287_9
Cites_doi 10.1097/aln.0000000000000398
10.5152/tjg.2014.4716
10.1016/j.ccm.2008.07.002
10.1002/jcb.21338
10.1016/j.intimp.2019.05.034
10.1074/jbc.m112.412031
10.1016/j.bbadis.2018.10.011
10.1097/shk.0000000000000978
10.26355/eurrev_201906_18094
10.3389/fimmu.2017.01021
10.1097/shk.0b013e3182391831
10.1155/2014/157376
10.1111/dom.12479
10.1007/s00125-011-2440-x
10.1016/j.intimp.2019.105898
10.7754/clin.lab.2016.160533
10.1056/nejm198908033210503
10.1159/000491887
10.1152/ajpcell.00356.2016
10.1186/s12933-014-0142-7
10.1186/s12933-020-01179-1
10.1001/jama.2016.0287
10.1152/ajpheart.00995.2008
10.1016/0014-5793(94)01430-9
10.1016/S0140-6736(19)31149-3
10.3760/cma.j.issn.2095-4352.2018.07.017
10.1016/j.abb.2019.07.008
10.1016/j.molmed.2007.09.002
10.1080/14712598.2017.1296131
10.7326/0003-4819-100-4-483
10.3389/fphar.2020.00090
ContentType Journal Article
Copyright 2021 The Authors. Published by American Chemical Society
2021 The Authors. Published by American Chemical Society.
2021 The Authors. Published by American Chemical Society 2021 The Authors
Copyright_xml – notice: 2021 The Authors. Published by American Chemical Society
– notice: 2021 The Authors. Published by American Chemical Society.
– notice: 2021 The Authors. Published by American Chemical Society 2021 The Authors
DBID N~.
AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1021/acsomega.0c06326
DatabaseName American Chemical Society (ACS) Open Access
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: N~.
  name: American Chemical Society (ACS) Open Access
  url: https://pubs.acs.org
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 2470-1343
EndPage 8278
ExternalDocumentID oai_doaj_org_article_5cd11797bf7e45aa93f8c9572702aabf
PMC8015136
33817486
10_1021_acsomega_0c06326
a312506758
Genre Journal Article
GroupedDBID 53G
ABFRP
ABUCX
ACS
ACSAX
ADACO
ADBBV
AFEFF
ALMA_UNASSIGNED_HOLDINGS
BCNDV
EBS
GROUPED_DOAJ
HYE
N~.
OK1
RPM
VF5
AAFWJ
AAHBH
AAYXX
ABBLG
ADUCK
AFPKN
AOIJS
CITATION
M~E
NPM
7X8
5PM
ID FETCH-LOGICAL-a499t-e136f6f3939754aa6ee7295fc8eb4c3ca853ac29cf2fca884c620fbc6acf1b903
IEDL.DBID DOA
ISSN 2470-1343
IngestDate Wed Aug 27 01:19:04 EDT 2025
Thu Aug 21 14:14:06 EDT 2025
Fri Jul 11 07:36:32 EDT 2025
Wed Feb 19 02:26:04 EST 2025
Thu Apr 24 23:00:49 EDT 2025
Tue Jul 01 01:05:51 EDT 2025
Sun Apr 11 09:01:11 EDT 2021
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
License https://creativecommons.org/licenses/by-nc-nd/4.0
2021 The Authors. Published by American Chemical Society.
Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a499t-e136f6f3939754aa6ee7295fc8eb4c3ca853ac29cf2fca884c620fbc6acf1b903
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-6435-2724
OpenAccessLink https://doaj.org/article/5cd11797bf7e45aa93f8c9572702aabf
PMID 33817486
PQID 2508896890
PQPubID 23479
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_5cd11797bf7e45aa93f8c9572702aabf
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8015136
proquest_miscellaneous_2508896890
pubmed_primary_33817486
crossref_primary_10_1021_acsomega_0c06326
crossref_citationtrail_10_1021_acsomega_0c06326
acs_journals_10_1021_acsomega_0c06326
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-03-30
PublicationDateYYYYMMDD 2021-03-30
PublicationDate_xml – month: 03
  year: 2021
  text: 2021-03-30
  day: 30
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle ACS omega
PublicationTitleAlternate ACS Omega
PublicationYear 2021
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref6/cit6
ref3/cit3
ref27/cit27
ref18/cit18
ref11/cit11
ref25/cit25
ref16/cit16
ref29/cit29
ref32/cit32
ref23/cit23
ref14/cit14
ref8/cit8
ref5/cit5
ref31/cit31
ref2/cit2
ref28/cit28
ref20/cit20
ref17/cit17
ref10/cit10
ref26/cit26
ref19/cit19
ref21/cit21
ref12/cit12
ref15/cit15
ref22/cit22
ref13/cit13
ref4/cit4
ref30/cit30
ref1/cit1
ref24/cit24
ref7/cit7
35694462 - ACS Omega. 2022 May 26;7(22):19040
References_xml – ident: ref10/cit10
  doi: 10.1097/aln.0000000000000398
– ident: ref18/cit18
  doi: 10.5152/tjg.2014.4716
– ident: ref5/cit5
  doi: 10.1016/j.ccm.2008.07.002
– ident: ref22/cit22
  doi: 10.1002/jcb.21338
– ident: ref14/cit14
  doi: 10.1016/j.intimp.2019.05.034
– ident: ref21/cit21
  doi: 10.1074/jbc.m112.412031
– ident: ref16/cit16
  doi: 10.1016/j.bbadis.2018.10.011
– ident: ref2/cit2
  doi: 10.1097/shk.0000000000000978
– ident: ref25/cit25
  doi: 10.26355/eurrev_201906_18094
– ident: ref6/cit6
  doi: 10.3389/fimmu.2017.01021
– ident: ref23/cit23
  doi: 10.1097/shk.0b013e3182391831
– ident: ref11/cit11
  doi: 10.1155/2014/157376
– ident: ref32/cit32
  doi: 10.1111/dom.12479
– ident: ref28/cit28
  doi: 10.1007/s00125-011-2440-x
– ident: ref24/cit24
  doi: 10.1016/j.intimp.2019.105898
– ident: ref19/cit19
  doi: 10.7754/clin.lab.2016.160533
– ident: ref9/cit9
  doi: 10.1056/nejm198908033210503
– ident: ref17/cit17
  doi: 10.1159/000491887
– ident: ref20/cit20
  doi: 10.1152/ajpcell.00356.2016
– ident: ref26/cit26
  doi: 10.1186/s12933-014-0142-7
– ident: ref13/cit13
  doi: 10.1186/s12933-020-01179-1
– ident: ref1/cit1
  doi: 10.1001/jama.2016.0287
– ident: ref7/cit7
  doi: 10.1152/ajpheart.00995.2008
– ident: ref27/cit27
  doi: 10.1016/0014-5793(94)01430-9
– ident: ref29/cit29
  doi: 10.1016/S0140-6736(19)31149-3
– ident: ref3/cit3
  doi: 10.3760/cma.j.issn.2095-4352.2018.07.017
– ident: ref30/cit30
  doi: 10.1016/j.abb.2019.07.008
– ident: ref31/cit31
  doi: 10.1016/j.intimp.2019.05.034
– ident: ref8/cit8
  doi: 10.1016/j.molmed.2007.09.002
– ident: ref12/cit12
  doi: 10.1080/14712598.2017.1296131
– ident: ref4/cit4
  doi: 10.7326/0003-4819-100-4-483
– ident: ref15/cit15
  doi: 10.3389/fphar.2020.00090
– reference: 35694462 - ACS Omega. 2022 May 26;7(22):19040
SSID ssj0001682826
Score 2.3041065
Snippet Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition....
Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition. Inflammatory response and...
Background and purpose: Sepsis is a severe infection-induced disease with multiple organ failure, and sepsis-induced cardiomyopathy is a fatal condition....
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
acs
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 8271
SummonAdditionalLinks – databaseName: American Chemical Society Journals
  dbid: ACS
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELWgHOBSvunypSDBgUO2ju04sTiVhaogQEilUm-WPbFL220Wkd1D--s7481u2VJVPSaxE9sz1jzH4_cYe2skhk0BPK9Jw500rHMPIuTeA3jQVeRJDuj7D72zp77ul_sXNDmXd_BFsemgm5yEAzfkgOFU6NvsjtAYZggGjXYv_qdoXDskdTWhKp4XUsl-V_Kql1Asgm4lFiXK_qtw5uV0yX_iz_b9uZBRl2gLKe3keDib-iGc_U_qeIOuPWDrPQzNtuZ-85DdCu0jdne0UH97zD58mo3dAbllE7KtMR1CJ1Saffu5m5PcB4Qm-9IeoUWywzYbpazWk9MJnGKhJ2xv-_Ov0U7eCy3kDhc80zwUUkcdpUFwUirndAiIuSm7K3gFEhzGdAfCQBQRL2oFWvCIpnQQC2-4fMrW2kkbNljmQjQE22LQQTVNND7ZpXE1LxtXFAP2Dntt-4nS2bQHLgq7GArbD8WAbS5MY6FnKyfRjPE1Nd4va_yZM3VcU_YjWXtZjji20w20ju2nrC2hIb68yscqqNI5I2MNpqzoBJ9zPg7Ym4WvWDQObbS4NkxmnRWEeo2uDR-wZ3PfWX5KEiWiqrEJ1YpXrbRl9Ul7-DvxfiOYKNFSz284hC_YPUEJOHSAkr9ka9O_s_AKEdTUv05T5xxnwxgY
  priority: 102
  providerName: American Chemical Society
Title Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes
URI http://dx.doi.org/10.1021/acsomega.0c06326
https://www.ncbi.nlm.nih.gov/pubmed/33817486
https://www.proquest.com/docview/2508896890
https://pubmed.ncbi.nlm.nih.gov/PMC8015136
https://doaj.org/article/5cd11797bf7e45aa93f8c9572702aabf
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagF7gg3iyPKkhw4JCu4yROLE5laVUQrZBKpd6s8cQuRdts1d099NLfzoyTrHYRKhculuLYymhmkvkcj78R4p3JKWwqlGnNNdy5hnXqUPnUOUSHugoylgM6PNIHJ8XX0_J0rdQX54R19MCd4sYlNsxaVrlQ-aIEMHmo0ZQVn6MCcIG_vtLItcVU_LuiaSWhhn1JimNjwPnswp_BjkSKysylcJe6NqJRJO3_G9L8M2FyLQLtPxQPeuiY7HYiPxJ3fPtY3JsMFdueiI-fl1M4Y1dqfLI75YPjjCSTb9-PUy7Rgb5JvrS_SIvJeZtMYibqxfUMr2nQU3Gyv_djcpD2xRFSoEXKIvVZroMOuSFAURYA2nvCyZyR5V2BOQLFYUBlMKhAF3WBWslA6gcMmTMyfya22lnrX4gEfDAMtYLXvmiaYFzUXgO1LBvIspF4T6qyvXPPbdy3VpkdVGp7lY7EeFCmxZ5hnAtdTG-Z8WE147Jj17hl7Ce2z2oc82LHDvIW23uL_Ze3jMTbwbqWjMObI9D62XJuFSNVo2sjR-J5Z-3Vo3KmMSxqEqHa8IMNWTbvtOc_I1c3AYCSLPXyfwj_StxXnFHDJyLla7G1uFr6NwSJFm6blgST4-34DlB7eLNH7dHNzm_MgA_C
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELVKOZQL35TlM0hw4JBt4jhOLE7LQrWFbYVoK_Vm2RO7lG6zFdk9lF_PjDfZslVVwTGOk9ieseY5Hr_H2FuVYdjkkMQlabiThnVsgbvYWgALsvBJkAPa3ZOjQ_HlKD9aY2l3FgYb0eCbmrCJf8kukG5h2fTMHZt-AhhVubzFbudSSFJrGAz3L3-rSFxCBJE1LookTjORtZuT172EQhI0KyEpMPdfBzevZk3-FYa277Hvyw6E7JPT_nxm-_D7Crfjf_XwPrvbgtJosPCiB2zN1Q_ZxrDTgnvEPnyaT8wxOWnlosGEjqQTRo3G3_ZjEv8AV0U79U-0T3RSR8OQ43p2MYULrPSYHW5_PhiO4lZ2ITa4_JnFLs2klz5TCFVyYYx0DhE45Xo5KyADgxHeAFfguceLUoDkiUfDGvCpVUn2hK3X09o9ZZFxXhGI8046UVVe2WCeypRJXpk07bF32GvdTptGhx1xnupuKHQ7FD221VlIQ8tdThIakxueeL984nzB23FD3Y9k9GU9YtwOBWgh3U5gnUNF7HmF9YUTuTEq8yWovKDzfMZY32NvOpfRaBzadjG1m84bzQkDK1mqpMc2Fy60_FRGBImixCYUK8610pbVO_XJj8ACjtAiR0s9-8chfM02Rge7Yz3e2fv6nN3hlJpDRyuTF2x99mvuXiK2mtlXYTb9Ad79IHo
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwEB2VIgEXvgvLZ5DgwCHbxEmcWJyWLasWSlWpFPVm2RO7FLbZiuweyq9nxptd2Kqq4BjHSWzPWPMcj98DeK0yCpsCk7hiDXfWsI4tChdbi2hRlj4JckCf9-T2Yf7xqDhag2JxFoYa0dKb2rCJz7P6rPYdw0C6SeWTU3ds-glSZBXyGlwnPJKyYsNgePDn14qkZUQQWhN5mcRplmfdBuVlL-GwhO1KWArs_ZdBzouZk3-FotEd-LrsRMhA-dGfTW0ff13gd_zvXt6F2x04jQZzb7oHa665DzeHC024B_BuazY2x-ystYsGYz6azlg12t0_iFkEBF0d7TTfyU7RSRMNQ67r6fkEz6nSQzgcffgy3I47-YXY0DJoGrs0k176TBFkKXJjpHOExDnny9kcMzQU6Q0KhV54uqhylCLxZGCDPrUqyTZgvZk07jFExnnFYM476fK69soGE9WmSorapGkP3lCvdTd9Wh12xkWqF0Ohu6HowebCSho7DnOW0hhf8cTb5RNnc_6OK-q-Z8Mv6zHzdiggK-luIusCa2bRK60vXV4YozJfoSpKPtdnjPU9eLVwG03G4e0X07jJrNWCsbCSlUp68GjuRstPZUyUmFfUhHLFwVbasnqnOfkW2MAJYhRkqSf_OIQv4cb-1kjv7ux9egq3BGfo8AnL5BmsT3_O3HOCWFP7Ikyo3-1zIvQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dulaglutide+Alleviates+LPS-Induced+Injury+in+Cardiomyocytes&rft.jtitle=ACS+omega&rft.au=Wang%2C+Rijun&rft.au=Wang%2C+Ning&rft.au=Han%2C+Yuping&rft.au=Xu%2C+Jiyao&rft.date=2021-03-30&rft.issn=2470-1343&rft.eissn=2470-1343&rft.volume=6&rft.issue=12&rft.spage=8271&rft.epage=8278&rft_id=info:doi/10.1021%2Facsomega.0c06326&rft.externalDBID=n%2Fa&rft.externalDocID=10_1021_acsomega_0c06326
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2470-1343&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2470-1343&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2470-1343&client=summon